Table 5.

Tumor Recurrence Rates in Patients and Tumors With Potential Risk Factors for Recurrence^a

	Recurrence Rate, % (No. of Recurrent Tumors/ No. of Tumors)

Characteristic^b	Characteristic Not Present	Characteristic Present
Tumors Treated With ED&C (n=127)
Patient immunocompromised^c	1.6 (2/124)	0 (0/3)
Squamous cell carcinoma	1.8 (2/110)	0 (0/17)
Tumor diameter > 10 mm^d	2.2 (1/46)	0 (0/21)
Tumor location in H-zone of the face^d,^e	1.9 (2/103)	0 (0/22)
Histologic risk factor for recurrence^f	1.6 (2/125)	0 (0/2)

Tumors Treated With Excision (n=309)
Patient immunocompromised^c	4.0 (12/300)	11.1 (1/9)
Squamous cell carcinoma	4.4 (9/204)	3.8 (4/105)
Tumor diameter > 10 mm^d	4.8 (7/145)	4.0 (5/126)
Tumor location in H-zone of the face^d,^e	3.1 (6/197)	6.4 (7/110)
Histologic risk factor for recurrence^f	4.5 (11/245)	3.1 (2/64)

Tumors Treated With Mohs Surgery (n=172)
Patient immunocompromised^c	3.1 (5/163)	11.1 (1/9)
Squamous cell carcinoma	3.1 (4/129)	4.7 (2/43)
Tumor diameter > 10 mm^d	3.2 (4/127)	2.4 (1/41)
Tumor location in H-zone of the face^d,^e	0 (0/36)	4.4 (6/136)
Histologic risk factor for recurrence^f	4.3 (6/141)	0 (0/31)

Abbreviation: ED&C, electrodessication and curettage.

Adapted from National Comprehensive Cancer Network guidelines.⁹

For each characteristic, P > .20.

Described in the medical record as “immunocompromised” or as having received an organ transplant or as having human immunodeficiency virus infection/AIDS.

Numbers of patients and/or tumors for which data on the following characteristics were missing, 103, diameter; 4, H-zone.

Facial areas regarded to be at higher risk for tumor recurrence.⁸

For basal cell carcinomas, histopathologic reading described perineural involvement or morpheaform, sclerosing, mixed infiltrative, or micronodular features. For squamous cell carcinomas, histopathologic reading described perineural involvement, poor differentiation, Clark level IV or V, or adenoid, adenosquamous, or desmoplastic features.